{"schema_version":"1","generated_at":"2026-11-20T18:57:14.668Z","data_as_of":null,"url":"https://www.findmykol.com/kol/mouhammed-habra","json_url":"https://www.findmykol.com/kol/mouhammed-habra/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"mouhammed-habra","name":"Mouhammed Habra","credential":"MD","specialty":"Endocrinology, Diabetes & Metabolism","specialty_raw":"Endocrinology, Diabetes & Metabolism","therapeutic_area":"Endocrinology/Metabolic","therapeutic_areas":["Endocrinology/Metabolic"],"institution":"The University of Texas MD Anderson Cancer Center","institution_url":"https://www.findmykol.com/institution/the-university-of-texas-md-anderson-cancer-center","city":"Houston","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Mouhammed Habra is an Endocrinology/Metabolic physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 232 publications with 9,946 citations (h-index 47); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Endocrinology/Metabolic"]},"scholarship":{"works_count":232,"cited_by_count":9946,"h_index":47,"latest_activity_year":2025,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05634577","title":"A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma","phase":"PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT05634577","trial_url":"https://www.findmykol.com/trial/NCT05634577"},{"nct":"NCT03370718","title":"Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT03370718","trial_url":"https://www.findmykol.com/trial/NCT03370718"}],"source":"trials"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":10,"shown":3,"withheld":7,"rows":[{"payer":"Exelixis","program_year":2025,"amount_usd":20064,"payment_count":1},{"payer":"RECORDATI_RARE_DISEASES_INC.","program_year":2025,"amount_usd":3850,"payment_count":1},{"payer":"Merck & Co.","program_year":2024,"amount_usd":111150.4,"payment_count":1}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":5,"areas_shown":3,"areas":[{"area":"Hormonal (systemic)","share_pct":64.1,"classes_total":2,"classes":[{"class":"l-Thyroxine","setting":"prescribed","share_pct":60.6,"drugs":[{"name":"Levothyroxine Sodium","share_pct":80.1},{"name":"Synthroid","share_pct":19.9}],"max_beneficiaries":61},{"class":"Vasopressin Analog","setting":"prescribed","share_pct":3.5,"drugs":[{"name":"Desmopressin Acetate","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":13.7,"classes_total":2,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":9.2,"drugs":[{"name":"Lenvima","share_pct":51.7},{"name":"Tafinlar","share_pct":48.3}],"max_beneficiaries":null},{"class":"Other antineoplastic agents","setting":"prescribed","share_pct":4.4,"drugs":[{"name":"Lysodren","share_pct":100}],"max_beneficiaries":null}]},{"area":"Sensory organs","share_pct":8.3,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":8.3,"drugs":[{"name":"Hydrocortisone","share_pct":100}],"max_beneficiaries":15}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns","year":2021,"journal":"Endocrine Related Cancer","source_url":"https://doi.org/10.1530/erc-20-0513","status":"verified"},{"title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","year":2020,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1136/jitc-2019-000347","status":"verified"},{"title":"Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas","year":2020,"journal":"Cancers","source_url":"https://doi.org/10.3390/cancers12082307","status":"verified"},{"title":"Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib","year":2020,"journal":"The Journal of Clinical Endocrinology & Metabolism","source_url":"https://doi.org/10.1210/clinem/dgz318","status":"verified"},{"title":"American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach","year":2020,"journal":"Endocrine Practice","source_url":"https://doi.org/10.4158/dscr-2020-0567","status":"verified"}],"source":"works"},"similar":[{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Gabriel Hortobagyi","slug":"gabriel-hortobagyi","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gabriel-hortobagyi","json_url":"https://www.findmykol.com/kol/gabriel-hortobagyi/profile.json"},{"name":"Anil Sood","slug":"anil-sood","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/anil-sood","json_url":"https://www.findmykol.com/kol/anil-sood/profile.json"},{"name":"Jaffer Ajani","slug":"jaffer-ajani","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jaffer-ajani","json_url":"https://www.findmykol.com/kol/jaffer-ajani/profile.json"},{"name":"Yousef Saleh Khader","slug":"yousef-khader","institution":"Jordan University of Science and Technology","url":"https://www.findmykol.com/kol/yousef-khader","json_url":"https://www.findmykol.com/kol/yousef-khader/profile.json"},{"name":"Jens Juul Holst","slug":"jens-holst","institution":"University of Copenhagen","url":"https://www.findmykol.com/kol/jens-holst","json_url":"https://www.findmykol.com/kol/jens-holst/profile.json"},{"name":"Victor Montori","slug":"victor-montori","institution":"Mayo Clinic","specialty":"Endocrinology, Diabetes & Metabolism","url":"https://www.findmykol.com/kol/victor-montori","json_url":"https://www.findmykol.com/kol/victor-montori/profile.json"},{"name":"Christos Mantzoros","slug":"christos-mantzoros","institution":"Harvard Medical School","specialty":"Endocrinology, Diabetes & Metabolism","url":"https://www.findmykol.com/kol/christos-mantzoros","json_url":"https://www.findmykol.com/kol/christos-mantzoros/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":7,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}